WO2022202603A1 - 多孔質吸着材料、およびそれを用いたバイオ医薬品精製用分離カラム、ならびに、バイオ医薬品の製造方法 - Google Patents
多孔質吸着材料、およびそれを用いたバイオ医薬品精製用分離カラム、ならびに、バイオ医薬品の製造方法 Download PDFInfo
- Publication number
- WO2022202603A1 WO2022202603A1 PCT/JP2022/012248 JP2022012248W WO2022202603A1 WO 2022202603 A1 WO2022202603 A1 WO 2022202603A1 JP 2022012248 W JP2022012248 W JP 2022012248W WO 2022202603 A1 WO2022202603 A1 WO 2022202603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- porous
- adsorption
- polymer
- adsorbent material
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 244
- 239000003463 adsorbent Substances 0.000 title claims abstract description 82
- 229960000074 biopharmaceutical Drugs 0.000 title claims abstract description 60
- 238000000926 separation method Methods 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims description 87
- 238000004519 manufacturing process Methods 0.000 title claims description 29
- 229920000642 polymer Polymers 0.000 claims abstract description 144
- 238000001179 sorption measurement Methods 0.000 claims description 174
- 102000004169 proteins and genes Human genes 0.000 claims description 172
- 108090000623 proteins and genes Proteins 0.000 claims description 172
- 239000011148 porous material Substances 0.000 claims description 114
- 230000002401 inhibitory effect Effects 0.000 claims description 70
- 239000002994 raw material Substances 0.000 claims description 27
- 239000012528 membrane Substances 0.000 claims description 26
- 239000012510 hollow fiber Substances 0.000 claims description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 23
- 238000005259 measurement Methods 0.000 claims description 23
- 239000000356 contaminant Substances 0.000 claims description 19
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 claims description 18
- 230000002209 hydrophobic effect Effects 0.000 claims description 16
- 238000005011 time of flight secondary ion mass spectroscopy Methods 0.000 claims description 15
- 238000002042 time-of-flight secondary ion mass spectrometry Methods 0.000 claims description 15
- 229920001567 vinyl ester resin Polymers 0.000 claims description 13
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 238000001228 spectrum Methods 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 3
- 239000013315 hypercross-linked polymer Substances 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 17
- 239000000835 fiber Substances 0.000 description 67
- 239000000243 solution Substances 0.000 description 59
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical group CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000306 component Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000000178 monomer Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- 229920005604 random copolymer Polymers 0.000 description 18
- 238000009987 spinning Methods 0.000 description 17
- 150000002500 ions Chemical group 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 14
- 239000004926 polymethyl methacrylate Substances 0.000 description 14
- 239000011550 stock solution Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- -1 polyethylene Polymers 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 12
- 239000012228 culture supernatant Substances 0.000 description 12
- 229920001477 hydrophilic polymer Polymers 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 229940125644 antibody drug Drugs 0.000 description 11
- 238000005345 coagulation Methods 0.000 description 11
- 230000015271 coagulation Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 125000001183 hydrocarbyl group Chemical group 0.000 description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 150000002148 esters Chemical group 0.000 description 8
- 239000004793 Polystyrene Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- 229920002223 polystyrene Polymers 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 6
- LZWYWAIOTBEZFN-UHFFFAOYSA-N ethenyl hexanoate Chemical group CCCCCC(=O)OC=C LZWYWAIOTBEZFN-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001788 irregular Effects 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010191 image analysis Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229920002492 poly(sulfone) Polymers 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 238000004804 winding Methods 0.000 description 4
- MXRGSJAOLKBZLU-UHFFFAOYSA-N 3-ethenylazepan-2-one Chemical compound C=CC1CCCCNC1=O MXRGSJAOLKBZLU-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000011118 depth filtration Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000010069 protein adhesion Effects 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- PDWSMLNAQOFQAV-UHFFFAOYSA-N 4-ethenylbenzenesulfonic acid 2-methyl-1-oxoprop-2-ene-1-sulfonic acid Chemical compound CC(=C)C(=O)S(O)(=O)=O.OS(=O)(=O)c1ccc(C=C)cc1 PDWSMLNAQOFQAV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229920005603 alternating copolymer Polymers 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 229910003481 amorphous carbon Inorganic materials 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- YCUBDDIKWLELPD-UHFFFAOYSA-N ethenyl 2,2-dimethylpropanoate Chemical group CC(C)(C)C(=O)OC=C YCUBDDIKWLELPD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 150000002763 monocarboxylic acids Chemical class 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920005672 polyolefin resin Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 1
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229910004530 SIMS 5 Inorganic materials 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical group CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- ABBZJHFBQXYTLU-UHFFFAOYSA-N but-3-enamide Chemical compound NC(=O)CC=C ABBZJHFBQXYTLU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- AFIQVBFAKUPHOA-UHFFFAOYSA-N ethenyl 2-methoxyacetate Chemical group COCC(=O)OC=C AFIQVBFAKUPHOA-UHFFFAOYSA-N 0.000 description 1
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical group CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
- CMDXMIHZUJPRHG-UHFFFAOYSA-N ethenyl decanoate Chemical group CCCCCCCCCC(=O)OC=C CMDXMIHZUJPRHG-UHFFFAOYSA-N 0.000 description 1
- BLZSRIYYOIZLJL-UHFFFAOYSA-N ethenyl pentanoate Chemical group CCCCC(=O)OC=C BLZSRIYYOIZLJL-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- XFTALRAZSCGSKN-UHFFFAOYSA-M sodium;4-ethenylbenzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=C(C=C)C=C1 XFTALRAZSCGSKN-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- KOZCZZVUFDCZGG-UHFFFAOYSA-N vinyl benzoate Chemical group C=COC(=O)C1=CC=CC=C1 KOZCZZVUFDCZGG-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28033—Membrane, sheet, cloth, pad, lamellar or mat
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28033—Membrane, sheet, cloth, pad, lamellar or mat
- B01J20/28038—Membranes or mats made from fibers or filaments
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28078—Pore diameter
- B01J20/2808—Pore diameter being less than 2 nm, i.e. micropores or nanopores
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28078—Pore diameter
- B01J20/28085—Pore diameter being more than 50 nm, i.e. macropores
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/321—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/44—Materials comprising a mixture of organic materials
- B01J2220/445—Materials comprising a mixture of organic materials comprising a mixture of polymers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/14—Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/26—Mass spectrometers or separator tubes
- H01J49/34—Dynamic spectrometers
- H01J49/40—Time-of-flight spectrometers
Definitions
- the present invention relates to a porous adsorption material, a separation column for purifying biopharmaceuticals using the same, and a method for producing biopharmaceuticals.
- Porous materials typified by activated carbon and silica gel, are materials with fine pores and have the property of easily adsorbing various substances. Taking advantage of this property, it is used as a deodorant, a desiccant, and industrially for the separation of substances.
- Protein separation is used in various fields, such as the manufacturing process of chemicals, foods, pharmaceuticals, and cosmetics, and the removal of pathogenic substances and environmental pollutants.
- Methods for separating proteins include mechanical or physical methods such as centrifugation and sedimentation, and methods using separation materials such as solvent extraction, adsorption, and chromatography.
- Protein adsorption materials used for protein separation are required to have high adsorption capacity, to be resistant to clogging and deterioration due to adsorption of proteins, etc. to the separation material, and to exhibit stable performance for a long period of time.
- the concentration of antibodies in the manufacturing process of biopharmaceuticals is two to three times higher than that in blood, depending on the process. Therefore, when a protein-adsorbing material is used in the manufacturing process of biopharmaceuticals, it is required not only to have a high adsorption capacity but also to be more resistant to clogging and deterioration than in the case of adsorbing substances in blood.
- Methods for improving the adsorption capacity of protein-adsorbing materials include increasing the adsorption capacity and chemically modifying the surface of the adsorbing material to improve adsorption selectivity.
- a technique using a porous solid fiber having a modified cross section as a protein adsorbing material has been disclosed (Patent Document 1). It describes a method for providing an adsorbent material having high adsorption performance by increasing the surface area per unit volume by making the fibers have an irregular cross-section with a specific shape.
- protein-adsorbing materials tend to adsorb proteins that are not targets of adsorption on the surface of the material. If the protein-adsorbing material has pores, the protein adsorbed on the surface of the material enters into the pores to change the pore size or block access to the pores, thereby hindering the adsorption of the target protein. It is feared that the adsorption performance will be reduced.
- Patent Document 2 describes a method of providing a protein-adsorbing material with high blood compatibility while suppressing a decrease in protein-adsorbing capacity by fixing a nitrogen-containing polymer containing a carboxylic acid vinyl ester on the surface.
- Patent Document 3 by supporting a polymer containing a polysulfone-based polymer as a main component and containing a monocarboxylic acid vinyl ester unit on the surface, proteins such as antibodies and viruses are prevented while suppressing clogging of proteins.
- a method for providing a porous hollow fiber membrane capable of separating such as at low pressure in a short time is described.
- Patent Document 4 by supporting a polymer containing a charged monomer and a monomer having a specific structure as monomer units on the surface of a porous bead, the hydrophilicity of the polymer makes the bead pores excessively hydrophilic. It prevents the adsorption of hydrophobic proteins from being hindered and the pores are blocked by the polymer, preventing the adsorption from deteriorating, and improving the blood compatibility while maintaining the adsorption of the porous beads. A method is described for providing adsorbent beads capable of.
- Patent Document 5 a specific amount of hydrophilic polymer resin is immobilized on the surface pores of a porous adsorption substrate by an anchor effect, thereby adjusting the balance between hydrophilicity and hydrophobicity, thereby adsorbing blood cells.
- An adsorbent for removing blood cells capable of adsorbing and removing blood cell components while reducing pressure loss in the device and preventing blood coagulation in the adsorber, and a method for providing a manufacturing method thereof are described.
- Patent Document 1 the surface of the porous fiber is not treated with a hydrophilic polymer or the like, and proteins that are not the target of adsorption adhere to the surface of the fiber, preventing the target protein from approaching the pores and adsorbing the target protein. There is concern that the amount will decrease.
- Patent Documents 2 to 5 a hydrophilic polymer is carried on the surface of the protein-adsorbing material in order to suppress protein adhesion to the surface of the protein-adsorbing material.
- the amount of hydrophilic polymer on the material surface is specified for controlling the adsorption and non-adsorption of proteins on the material surface, and the thickness of the hydrophilic polymer in the depth direction of the material is not described. .
- the hydrophilic polymer in the protein adsorption material is thick in the depth direction of the material, the hydrophilic polymer penetrates into the pores on the surface to change the pore size and suppress protein adhesion. There is a possibility that the amount of protein adsorbed in the pores may be reduced by hindering the adsorption of the protein to be adsorbed. Conversely, if the thickness of the hydrophilic polymer in the depth direction of the material is too thin, proteins that are not targets of adsorption adhere to the surface of the material, preventing the proteins that are targets of adsorption from approaching the pores. The amount of adsorbed protein may decrease.
- the inventors conducted repeated studies and found that by controlling the thickness of the layer containing a nonionic polymer having a hydrophilic unit in the depth direction of the material within a specific range, the adsorption of proteins that are not the target of adsorption to the material surface can be prevented. It was found that a protein adsorbing material with high separation selectivity can be obtained while suppressing clogging.
- the present invention is a porous adsorption used for adsorbing and removing contaminants from a biopharmaceutical raw material solution with high separation selectivity, which is capable of adsorbing target proteins while suppressing clogging due to adsorption of proteins not to be adsorbed. Intended to provide material.
- the present invention has found that by having a layer containing a nonionic polymer, separation selectivity is achieved while suppressing clogging due to adsorption of proteins that are not the target of adsorption to the material surface. It has been found that a highly porous adsorbent material used for adsorbing and removing contaminants from biopharmaceutical raw material solutions can be obtained. That is, the present invention is as follows.
- a porous adsorption material used to adsorb and remove contaminants from a biopharmaceutical raw material solution the porous adsorption material having a layer containing a nonionic polymer on at least one surface.
- porous adsorption material of the present invention it is possible to adsorb the target protein while suppressing clogging due to adsorption of proteins not to be adsorbed. It can be used suitably for materials.
- the porous adsorption material of the present invention is a porous adsorption material having a layer containing a nonionic polymer on at least one surface.
- the present invention is preferably a protein-adsorbing material having pores, having a layer containing a biocomponent-adhesion-suppressing polymer on at least one surface, and a cross-section of the protein-adsorbing material having time-of-flight secondary ion
- the thickness of the layer containing the biological component adhesion-inhibiting polymer is 3 ⁇ m or less when the composition is analyzed by mass spectrometry (TOF-SIMS).
- the porous adsorption material generally has the property of easily adsorbing various substances as a material with fine pores.
- these porous adsorption material adsorbs are, for example, substances that are understood as contaminants in raw material solutions of biopharmaceuticals, and specific examples include those described later, as well as other proteins, lipids, and water.
- a protein-adsorbing material refers to a material that has the ability to adsorb proteins.
- the material constituting the porous adsorption material or protein adsorption material is not particularly limited, polymethyl methacrylate (hereinafter referred to as PMMA), polystyrene, polyethylene, polypropylene, cellulose such as cellulose acetate, cellulose diacetate, and cellulose triacetate
- PMMA polymethyl methacrylate
- polystyrene polyethylene
- polypropylene cellulose such as cellulose acetate, cellulose diacetate, and cellulose triacetate
- Polycarbonate polyurethane
- polyvinyl chloride polyvinylidene fluoride and other fluororesins
- polyacrylonitrile polyethylene terephthalate and other polyesters
- polyamides silicon dioxide used in quartz and silica gel
- aluminosilicates used in zeolites etc.
- the protein-adsorbing material is preferably composed of a base material containing at least one selected from PMMA, polystyrene, polypropylene, silicon dioxide, aluminosilicate and amorphous carbon because it exhibits excellent adsorption performance.
- a substrate containing at least one selected from PMMA, polystyrene and polypropylene is more preferable as a substrate constituting the protein-adsorbing material because it efficiently adsorbs the protein to be adsorbed.
- PMMA is preferable because a base material having uniform pore sizes can be obtained by mixing an isotactic body and a syndiotactic body to form a stereocomplex, which is a steric complex.
- polystyrene and polypropylene may be core-sheath composite fibers having a core component of polystyrene and a sheath component of polystyrene and polypropylene.
- the shapes of the materials that make up the porous adsorbent material or protein adsorbent material include fibers, nonwoven fabrics, woven fabrics, knitted fabrics, particles, films, molded articles, and the like. Among them, fibers can increase the specific surface area by reducing the fiber diameter, so the shape of the porous adsorption material or protein adsorption material of the present invention is preferably a fiber shape.
- the fiber may be either a solid fiber having no voids continuous in the longitudinal direction or a hollow fiber having voids.
- the specific surface area is small and the protein to be adsorbed may not be efficiently adsorbed.
- the inside of the hollow fiber is more likely to be adsorbed than the outside. Since the flow rate of the solution containing a certain protein and a non-target protein is slow, the inside of the hollow fiber efficiently adsorbs the protein to be adsorbed without contacting the solution containing the protein to be adsorbed and the non-target protein. may not be sufficiently removed.
- the solid fiber may consist of a single component or two or more components, and may have any form such as an asymmetric structure, a uniform structure, a sea-island structure, or a core-sheath structure. Among them, from the viewpoint of increasing the amount of protein adsorbed, a uniform structure having pores continuous to the inside of the solid yarn is preferred.
- the shape of the porous adsorption material or the protein adsorption material is a fiber such as a solid fiber or a hollow fiber
- the shape of the fiber cross section is not particularly limited, and may be circular or non-circular.
- fins are protrusions present in the outer peripheral portion of the cross section of the fiber.
- the upper limit is preferably 12 or less, more preferably 8 or less, and particularly preferably 6 or less. If the number of fins is too large, the gaps between the fins may be narrowed, the surface area per volume may be reduced, and the liquid to be treated may be difficult to contact between the fins.
- the fins of adjacent fibers may get stuck in each other, preventing contact between the fiber surface and the solution. Therefore, when fibers with irregular cross-sections are used as the protein adsorbing material, they are preferably mixed with circular or elliptical fibers having no fins.
- the porous adsorption material of the present invention is used to adsorb and remove contaminants from biopharmaceutical raw material solutions.
- Biopharmaceuticals refer to pharmaceuticals that are manufactured using biotechnology such as genetic recombination and cell culture, and that contain proteins such as antibodies, hormones, and enzymes as active ingredients.
- the active ingredients of biopharmaceuticals are produced by cells, from which a solution containing the active ingredients is separated.
- Biopharmaceutical raw material solution refers to this separated solution.
- Contaminants refer to substances other than the active ingredient contained in the biopharmaceutical raw material solution. Examples of contaminants include host cell proteins (hereinafter "HCP"), antibody degradation products, medium-derived components, DNA, viruses, free protein A, and the like.
- HCP host cell proteins
- the protein to be adsorbed by the protein-adsorbing material is not particularly limited, but examples include albumin, globulin, and fibrinogen.
- biopharmaceuticals such as antibody drugs using biotechnology such as cell culture technology
- many protein separation technologies such as affinity chromatography such as protein A column, ion exchange chromatography, and depth filtration are used.
- proteins to be adsorbed include cell-host-derived proteins (HCP), degradation products of antibodies, medium-derived components, DNA, virus particles, free protein A, and the like. is mentioned.
- the porous adsorption material of the present invention has a layer containing a nonionic polymer on at least one surface thereof.
- a nonionic polymer refers to a polymer that is neutral in charge as a whole. "Charge-neutral" means that the pH in solution is in the range of 6.0 to 7.5. Within this range, polymers containing zwitterions may be used.
- the solvent for preparing the solution may be water containing an organic solvent such as ethanol, in addition to water.
- hydrophilic polymers are more preferable.
- a hydrophilic polymer refers to a polymer having a hydrophilic functional group such as an ether group, an ester group, an amide group, a hydroxyl group, or a carboxyl group in the polymer structure. These functional groups preferably account for 9% or more by weight of the total weight of the polymer.
- biocomponent adhesion-inhibiting polymers are more preferable.
- the biological component adhesion-inhibiting polymer has the property that when a flat membrane is made from the polymer and brought into contact with human blood, the number of platelets adhered per area of 4.3 ⁇ 10 3 ⁇ m 2 is 20 or less. point to what is
- the method for producing a flat membrane from the polymer is not particularly limited, but as an example, a polysulfone base material is immersed in a polymer solution to be confirmed, and the polymer to be confirmed is crosslinked to the polysulfone base material by ⁇ -ray irradiation. It can be produced by a method of immobilizing by pressing.
- the platelet adhesion count is determined by immediately adding heparin to 50 U/ml, contacting the platelet membrane within 10 minutes after collecting, and shaking at 37° C. for 4 hours. Thereafter, the flat membrane is washed with physiological saline, blood components are fixed with glutaraldehyde physiological saline, and washed with distilled water. The flat film is dried under reduced pressure at room temperature of 0.5 Torr for 10 hours, and a Pt--Pd thin film is formed on the flat film surface by sputtering to obtain a sample.
- the flat membrane surface is observed with a scanning electron microscope at a magnification of 1500, and the number of adherent platelets per 4.3 ⁇ 10 3 ⁇ m 2 is counted.
- the average value of the adhered platelet counts in 10 different fields of view is defined as the adhered platelet count (platelets/4.3 ⁇ 10 3 ⁇ m 2 ).
- the number of adhered platelets is 20/4.3 ⁇ 10 3 ⁇ m 2 or less, preferably 10/4.3 ⁇ 10 3 ⁇ m 2 or less.
- the layer containing the biocomponent adhesion-inhibiting polymer may be present on the surface that comes into contact with the biocomponents first, especially when the biocomponents are separated using the porous adsorbent material or protein adsorbent material of the present invention.
- biocomponent refers to a substance that constitutes a living body, and specifically refers to proteins, lipids, carbohydrates, and the like.
- the method for contacting the biological component with the porous adsorbent material or the protein adsorbent material is not particularly limited as long as the porous adsorbent material or the protein adsorbent material and the biological component can be brought into contact with each other. Examples include a method of passing through a material or a protein-adsorbing material, a method of immersing a solution containing a biological component in a porous adsorption material or a protein-adsorbing material, and the like.
- the layer of the porous adsorbent material or protein adsorbent material containing the nonionic polymer or biocomponent adhesion-inhibiting polymer is thick, the biocomponent adhesion-inhibiting polymer enters into the pores on the surface, and the pore size increases. , or inhibits the adsorption of biocomponents, thereby reducing the amount of protein adsorbed in the pores. Therefore, the thickness of the layer containing the nonionic polymer or biocomponent adhesion-inhibiting polymer is preferably 5 ⁇ m or less, more preferably 3 ⁇ m or less.
- the thickness of the layer containing the nonionic polymer or the biocomponent adhesion-inhibiting polymer is preferably 1.5 ⁇ m or more, more preferably 2 ⁇ m or more.
- the thickness of the layer containing the nonionic polymer or biocomponent adhesion-suppressing polymer is a value obtained by compositional analysis of the cross section of the protein-adsorbing material by time-of-flight secondary ion mass spectrometry (TOF-SIMS).
- TOF-SIMS time-of-flight secondary ion mass spectrometry
- a method of combining preparation with TOF-SIMS depth profile measurement using an argon gas cluster ion beam (Ar-GCIB) or measurement using XPS can measure a thickness of up to 10 nm.
- the thickness of the layer containing the biocomponent adhesion-inhibiting polymer in the protein-adsorbing material of the present invention is not particularly limited as long as it is 3 ⁇ m or less.
- TOF-SIMS time-of-flight secondary ion mass spectrometry
- TOF- A composition analysis using a SIMS device detects a peak derived from the biocomponent adhesion-inhibiting polymer, so by analyzing its mass (m/z), it is possible to obtain knowledge about the abundance of the nonionic polymer or biocomponent adhesion-inhibiting polymer. is obtained, and the thickness of the layer containing the nonionic polymer or biocomponent adhesion-inhibiting polymer can be measured.
- the methods described in the Examples section can be used.
- pulsed ions are irradiated onto the sample surface placed in an ultra-high vacuum, and ions (secondary ions) emitted from the sample surface acquire a constant kinetic energy. through a time-of-flight mass spectrometer.
- ions secondary ions
- the ion species can be replaced with species characteristic of the nonionic polymer or biocomponent adhesion-inhibiting polymer used.
- the conditions for composition analysis by TOF-SIMS measurement are as follows.
- the measurement area is 50 ⁇ m ⁇ 50 ⁇ m
- the primary ion acceleration voltage is 25 kV
- the pulse width is 125.0 ns.
- the detection depth in this detection method is several nanometers or less.
- the detection depth in this analysis method is several nanometers or less. More specifically, it shall be measured according to "(1) TOF-SIMS measurement" described later.
- the amount of the nonionic polymer or biocomponent adhesion-inhibiting polymer present on the surface of the protein-adsorbing material can be quantified.
- the amount of nonionic polymer or biocomponent adhesion-inhibiting polymer present on the surface of the porous adsorbent material or protein adsorbent material is measured from the side of the layer containing the nonionic polymer or biocomponent adhesion-inhibiting polymer.
- the ratio of nitrogen atoms to 100 (atoms %) of all atoms detected by XPS can be used as an index.
- Porous adsorption material, nonionic polymer of protein adsorption material, or the ratio of nitrogen atoms to 100 total atoms (atom %) when measured by XPS from the side of the layer containing the biological component adhesion suppression polymer is too high. Then, the approach of the protein to be adsorbed to the pores of the porous adsorption material or the protein adsorption material is hindered, and the amount of protein adsorbed in the pores may decrease.
- the ratio of nitrogen atoms to 100 total atoms (% by number of atoms) measured by XPS is too small, proteins that are not the target of adsorption adhere to the surface of the material, and the proteins that are the target of adsorption approach the pores. may be hindered and the amount of protein adsorbed within the pores may be reduced. Therefore, when measured from the side of the layer containing the nonionic polymer or biocomponent adhesion-suppressing polymer, the ratio of nitrogen atoms to 100 (atomic %) of all atoms detected by XPS is 0.5 (atomic number %) to 8 (% by atomic number) or less.
- the value measured at an XPS measurement angle of 45° is used.
- regions up to a depth of about 10 nm from the surface are detected. More specifically, it is measured according to "(2) XPS measurement" described later.
- a porous adsorption material or protein adsorption material has pores for efficiently removing contaminants or proteins to be adsorbed.
- the porous adsorbent material or protein adsorbent material of the present invention is not particularly limited in shape or size as long as it has pores capable of adsorbing the target protein. If the average pore radius of is too small, the protein to be adsorbed cannot enter the pores, and if the average pore radius is too large, the pore surface area per unit volume becomes small. In some cases, the protein to be adsorbed cannot be efficiently adsorbed.
- the value of the average pore radius when the porous adsorption material or protein adsorption material of the present invention is measured with a differential scanning calorimeter (DSC) is not particularly limited, but the lower limit is preferably 1 nm or more, It is more preferably 1.5 nm or more, and particularly preferably 2.0 nm or more.
- the upper limit of the average pore radius of the protein-adsorbing material measured by DSC is preferably 100 nm or less, more preferably 40 nm or less, and particularly preferably 25 nm or less.
- the average pore radius of the porous adsorbent material or protein adsorbent material can be measured using a differential scanning calorimeter (DSC).
- DSC differential scanning calorimeter
- the porous adsorbent material or protein adsorbent material is quenched to -55°C and measured by heating up to 5°C at a rate of 0.3°C/min. Calculate the average pore radius.
- Average pore radius [nm] (33.30 - 0.3181 x (melting point of water - melting point determined from peak top temperature of curve) [°C]) / (melting point of water - determined from peak top temperature of curve melting point) [°C]
- the above measuring method is the same as that of Kazuhiro Ishikiriyama et al. ; JOURNAL OF COLLOID AND INTERFACE SCIENCE, 171, 103-111, (1995) is referred to.
- a fine particle having an optimum size for the porous adsorbent material or protein adsorbent material is required. It is preferable that there are many pores. If too large or too small pores are present, it may not be possible to efficiently adsorb the protein to be adsorbed.
- the protein-adsorbing material is observed with a scanning electron microscope (SEM), and image analysis is performed to measure the average pore size near the surface.
- SEM scanning electron microscope
- the average pore size ratio is preferably 0.5 or more, more preferably 0.8 or more.
- the ratio of the average pore size in the central portion to the average pore size in the vicinity of the surface is preferably 1.3 or less, more preferably 1.1 or less, when the protein-adsorbing material is observed with an SEM and subjected to image analysis for measurement. .
- the cross-section of the porous adsorbent material or protein adsorbent material refers to the biopharmaceutical raw material solution of the porous adsorbent material or protein adsorbent material, or the solution containing the protein to be adsorbed and the protein not to be adsorbed.
- a surface obtained by cutting perpendicular to the contact surface For example, in the case of fibers, it refers to a plane cut perpendicular to the longitudinal direction. Image analysis is performed by observing the central part and the vicinity of the surface of the cross section of the porous adsorbent material or protein adsorbent material.
- the pore radius near the surface is the pore radius at the surface of the porous adsorbent material or the protein adsorbent material, that is, at the perimeter of the cross section. More specifically, the ratio of the pore radius in field 2 of 225 ⁇ 225 pixels adjacent to field 1 in the direction perpendicular to the surface to the pore radius in field 1 of 225 ⁇ 225 pixels in contact with the surface is doubled. If less than, the field of view of 640 ⁇ 480 pixels that completely encompasses field of view 1 is called near surface. However, in the case of PMMA fiber, etc., there may be a dense layer on the surface, which has a very small pore radius.
- the pore radius should be optimized without variation for adsorption removal of the protein to be adsorbed, it is appropriate not to include such a layer portion in the above "near the surface". . Therefore, when the ratio of the pore radius in the field of view 2 to the pore radius in the field of view 1 is twice or more, the field of view of 640 ⁇ 480 pixels that completely covers the field of view 2 and does not include the field of view 1 at all is called the surface vicinity.
- the center of the straight line with the longest length is called the central part. Also find the average pore size in the center.
- the shape of the pore is not a perfect circle, it is assumed to be a perfect circle, and the pore radius is calculated from the pore area by the following formula.
- Pore radius at the center or near the surface [nm] (Pore area at the center or near the surface [nm 2 ]/ ⁇ ) 1/2 Porous adsorbent material or protein adsorbent material is cut at any five points, and measurements are taken at the center and near the surface, respectively, to obtain the pore radius. Pore diameter.
- the specific surface area of the porous adsorbent material represents the area of the surface with which the biopharmaceutical raw material solution containing the protein or the like to be adsorbed can come into contact with the adsorbent material, relative to the weight of the adsorbent material.
- the specific surface area of the porous adsorbent material is large, but if it is too large, the strength will decrease. From the above, it is preferably 0.001 m 2 /g or more, more preferably 0.01 m 2 /g or more, and even more preferably 0.05 m 2 /g or more. On the other hand, it is preferably 0.1 m 2 /g or less, more preferably 0.5 m 2 /g or less.
- the porous adsorption material or protein adsorption material is immersed in a solution containing proteins to be adsorbed and proteins not to be adsorbed. It can be determined by measuring the amount of protein to be adsorbed in the solution after a certain period of time has passed after immersion, and subtracting it from the amount of protein to be adsorbed in the solution before immersion.
- a porous adsorption material or protein adsorption material is incorporated into a module or column, a circuit is connected, a solution containing proteins to be adsorbed and proteins not to be adsorbed is circulated, and after a certain period of time, It can be obtained by measuring the amount of protein to be adsorbed in the solution and subtracting it from the amount of protein to be adsorbed in the solution before immersion.
- the method for measuring the amount of protein is not particularly limited, but includes the Lowry method, the bicinchoninic acid method, the ELISA method, the immunoturbidimetric method, and the like. Among them, the ELISA method and the immunoturbidimetric method are preferable because of their high specificity to the protein to be adsorbed.
- the layer placed on at least one surface of the protein-adsorbing material of the present invention contains a biocomponent adhesion-inhibiting polymer.
- biocomponent adhesion-inhibiting polymers include, but are not limited to, polyvinylpyrrolidone, polyethylene glycol, poly(2-methoxyethyl acrylate), and the like.
- the biological component adhesion-suppressing polymer contain nitrogen atoms.
- the form in which the nitrogen atoms are present is not particularly limited. It is preferable from the viewpoint of the effect of suppressing adhesion of biological components.
- the nonionic polymer or biocomponent adhesion-inhibiting polymer used in the present invention is preferably a copolymer consisting of a hydrophilic unit and a hydrophobic unit.
- the term "unit” refers to a repeating unit in a homopolymer or copolymer obtained by polymerizing a monomer.
- the hydrophilic unit refers to a polymer having a weight average molecular weight of 10,000 to 1,000,000, which is soluble in water when a polymer is produced solely from the monomers constituting the unit.
- “Soluble” refers to those having a solubility of greater than 0.1 g in 100 g of water at 20°C.
- the hydrophobic unit is preferably a monocarboxylic acid vinyl ester unit.
- the monocarboxylic acid means a compound composed of one carboxyl group and a hydrocarbon group bonded to the carbon atom of the carboxyl group, that is, a compound represented by "R-COOH" (R is a hydrocarbon group). do.
- the hydrocarbon group R in the monocarboxylic acid may be either an aliphatic hydrocarbon group or an aromatic hydrocarbon group, but from the viewpoint of ease of synthesis, an aliphatic hydrocarbon group, particularly a saturated aliphatic hydrocarbon It is preferably a group.
- the saturated aliphatic hydrocarbon group preferably has a linear structure or a branched structure, more preferably a linear structure.
- Examples of monocarboxylic acids in which the hydrocarbon group R in the monocarboxylic acid is an aromatic hydrocarbon group include benzoic acid and derivatives thereof.
- Examples of monocarboxylic acids in which the hydrocarbon group R in the monocarboxylic acid is a saturated aliphatic hydrocarbon group include acetic acid, propanoic acid and butyric acid.
- the saturated aliphatic hydrocarbon group includes not only linear structures such as ethyl group, n-propyl group, n-butyl group, n-pentyl group and n-hexyl group, but also branched structures such as isopropyl group and tertiary butyl group. or a cyclic structure such as a cyclopropyl group or a cyclobutyl group.
- the aliphatic chain may contain an ether bond, an ester bond, or the like.
- the hydrocarbon group R may have a hydrogen atom substituted with any substituent. It is preferred that the terminal hydrogen atoms are not substituted with anionic functional groups, as this may destabilize the , and induce attachment to the surface of the protein-adsorbing material.
- a small number of carbon atoms in the hydrocarbon group R in the monocarboxylic acid is preferable in terms of lowering the hydrophobicity of the monocarboxylic acid, reducing the hydrophobic interaction with proteins not to be adsorbed, and preventing adhesion. Therefore, when R is an aliphatic hydrocarbon group or an aromatic hydrocarbon group, the number of carbon atoms is preferably 1-20, more preferably 1-9, and even more preferably 2-5. When R is a saturated aliphatic hydrocarbon group, the compound having 1 carbon atom is acetic acid, and the compound having 2 carbon atoms is propanoic acid.
- the term "monocarboxylic acid vinyl ester unit” refers to a repeating unit in a homopolymer obtained by polymerizing a monocarboxylic acid vinyl ester monomer.
- a unit (repeating unit) represented by “—CH(OCO—R)—CH 2 —” (R is a hydrocarbon group having 1 to 20 carbon atoms) is preferable.
- R is the same as described for the monocarboxylic acid above, and preferred examples are also the same as above.
- the hydrocarbon group R having 2 to 20 carbon atoms in the monocarboxylic acid vinyl ester unit is preferably a saturated aliphatic hydrocarbon group or an aromatic hydrocarbon group. Among them, aliphatic hydrocarbon groups having 2 to 5 carbon atoms are preferred.
- Specific examples of the monocarboxylic acid vinyl ester unit in which the hydrocarbon group R having 2 to 20 carbon atoms in the monocarboxylic acid vinyl ester unit is a saturated aliphatic hydrocarbon group include a vinyl propanoate unit, a vinyl pivalate unit, A vinyl decanoate unit, a vinyl methoxyacetate unit, etc. are mentioned.
- Preferred examples include vinyl acetate units, vinyl propanoate units, vinyl butyrate units, vinyl pentanoate units, vinyl pivalate units, and vinyl hexanoate units, since it is preferable that they are not too hydrophobic.
- specific examples of the monocarboxylic acid vinyl ester unit in which R is aromatic include a vinyl benzoate unit and a substituted product thereof.
- the monomer constituting the hydrophobic unit includes at least a vinyl monocarboxylic acid ester, but may further include a unit selected from acrylic acid ester, methacrylic acid ester, vinyl- ⁇ -caprolactam, and the like.
- a monomer having a solubility of more than 10 g in 100 g of water at 20°C is more preferable.
- Such monomers include vinyl alcohol monomers, acryloylmorpholine monomers, vinylpyridine monomers, vinylimidazole monomers, vinylpyrrolidone monomers, and the like.
- monomers having an amide bond, an ether bond, or an ester bond are preferable because they are less hydrophilic than monomers having a carboxyl group or a sulfonic acid group and are easily balanced with a hydrophobic monomer.
- the biocomponent adhesion-inhibiting polymer contains a vinylpyrrolidone unit as the hydrophilic unit.
- the monomer constituting the hydrophobic unit includes at least a vinyl monocarboxylic acid ester, but may further include a unit selected from acrylic acid ester, methacrylic acid ester, vinyl- ⁇ -caprolactam, and the like.
- the number average molecular weight of the nonionic polymer or biocomponent adhesion-suppressing polymer is preferably 1,000 or more, more preferably 5,000 or more, from the viewpoint of sufficiently suppressing adhesion of proteins that are not targets of adsorption.
- the upper limit of the number average molecular weight of the biocomponent adhesion-inhibiting polymer is not particularly limited, but is preferably 1,000,000 or less, and 500,000 or less, from the viewpoint of avoiding a decrease in porosity introduced into the protein-adsorbing material. is more preferred, and 100,000 or less is even more preferred.
- the number average molecular weight of the homopolymer or copolymer can be measured by gel permeation chromatography (GPC).
- the molar fraction of the hydrophobic unit in the copolymer composed of the hydrophilic unit and the hydrophobic unit is preferably 10% or more and 90% or less, and 20% or more. 80% or less is more preferable, and 30% or more and 70% or less is even more preferable.
- the hydrophobic unit may be a monocarboxylic acid vinyl ester unit alone, or may further include other hydrophobic units.
- the calculation method of the said mole fraction performs nuclear magnetic resonance (NMR) measurement, for example, and calculates it from the peak area ratio of the peak corresponding to each component.
- NMR nuclear magnetic resonance
- a copolymer consisting of a vinyl monocarboxylic acid ester unit and a vinylpyrrolidone unit is particularly preferable as the biocomponent adhesion-suppressing polymer.
- the molar ratio of the vinylpyrrolidone unit and the monocarboxylic acid vinyl ester unit is preferably from 30:70 to 90:10, more preferably from 40:60 to 80:20, still more preferably from 50:50 to It is 70:30.
- Examples of the arrangement of units in the above copolymer include block copolymers, alternating copolymers, and random copolymers.
- alternating copolymers and random copolymers are preferable from the viewpoint that the uneven distribution of hydrophilic units and hydrophobic units in the entire copolymer is small.
- random copolymers are more preferable because they are easy to synthesize.
- Methods for forming a layer containing a biocomponent adhesion-inhibiting polymer on at least one surface of a protein-adsorbing material include a method of adding a biocomponent-adhesion-inhibiting polymer during production of the protein-adsorbing material, and a method of adding a biocomponent-adhesion-inhibiting polymer after production of the protein-adsorbing material. Methods of contacting the inhibiting polymer are included.
- the method of bringing the biocomponent adhesion-inhibiting polymer into contact with the protein-adsorbing material is preferable from the viewpoint that the layer containing the biocomponent adhesion-inhibiting polymer is present on at least one surface in an appropriate thickness without becoming too thick.
- Methods for bringing the biocomponent adhesion-inhibiting polymer into contact with the protein-adsorbing material include: immersing the protein-adsorbing material in the biocomponent-adhesion-inhibiting polymer solution; passing the biocomponent-adhesion-inhibiting polymer solution through the protein-adsorbing material; Examples include a method of spraying a biocomponent adhesion-inhibiting polymer solution with a spray or the like.
- a method of immersing the protein-adsorbing material in a biocomponent adhesion-inhibiting polymer solution and a method of passing the biocomponent-adhesion-inhibiting polymer solution through the protein-adsorbing material, because the biocomponent adhesion-inhibiting polymer can be evenly applied to the surface of the protein-adsorbing material. is preferred.
- the concentration of the biocomponent adhesion-inhibiting polymer in the biocomponent adhesion-inhibiting polymer solution is preferably 10 ppm or more, more preferably 100 ppm or more.
- the concentration of the biocomponent adhesion-inhibiting polymer in the solution is preferably 100,000 ppm or less, more preferably 10,000 ppm or less, and even more preferably 1,000 ppm or less.
- Water is preferable as the solvent used to prepare the biocomponent adhesion-inhibiting polymer solution.
- the biocomponent adhesion-inhibiting polymer to be used has low solubility in water, an organic solvent that does not dissolve the protein-adsorbing material, or a mixed solvent of water and an organic solvent that is compatible with water and does not dissolve the protein-adsorbing material. You may melt
- organic solvents that can be used in the above organic solvent or mixed solvent include, but are not limited to, alcoholic solvents such as methanol, ethanol, and propanol.
- a method for forming a layer containing a biocomponent adhesion-inhibiting polymer on a protein-adsorbing material it is desirable to chemically immobilize the biocomponent-adhesion-inhibiting polymer on the surface of the protein-adsorbing material.
- the method of immobilizing the biocomponent adhesion-inhibiting polymer on the surface of the protein-adsorbing material by a chemical method is not particularly limited.
- a method of introducing a reactive group such as an amino group or a carboxyl group into both the adsorbent material and the biocomponent adhesion-inhibiting polymer and allowing them to react can be mentioned.
- Methods for introducing reactive groups onto the surface of the protein adsorption material include a method of polymerizing a monomer having a reactive group to obtain a material having a reactive group on the surface, and a method of obtaining a material having a reactive group on the surface, followed by ozone treatment or plasma treatment to remove the reactive group. and the like.
- ⁇ -rays, ⁇ -rays, ⁇ -rays, X-rays, ultraviolet rays, electron beams, etc. can be used as radiation.
- radiation is applied to the protein-adsorbing material in a dried state.
- the irradiation dose of radiation is preferably 15 kGy or more, more preferably 25 kGy or more.
- the irradiation dose is preferably 100 kGy or less.
- An antioxidant may be used to suppress the cross-linking reaction during irradiation.
- An antioxidant means a substance that has the property of easily donating electrons to other molecules. Examples include water-soluble vitamins such as vitamin C, polyphenols, and alcoholic solvents such as methanol, ethanol, and propanol. but not limited to these. These antioxidants may be used alone or in combination of two or more. When antioxidants are used in protein-adsorbing materials, it is necessary to consider safety, so low-toxic antioxidants such as ethanol and propanol are preferably used.
- nonionic polymer on the surface of the porous material can be performed in the same manner as described above.
- the porous adsorption material or protein adsorption material of the present invention exhibits excellent protein adsorption performance, it can be applied to the step of recovering antibodies or the pretreatment step of the antibody recovery step using a protein A column. is.
- the size of antibodies is generally assumed to be 10-15 nm.
- the pore size of the protein-adsorbing material of the present invention is smaller than the size of the antibody, the antibody does not adsorb, and HCP having a size smaller than the antibody, degradation products of the antibody, medium-derived components, DNA, viruses, free protein A, etc. can be removed by adsorption.
- the porous adsorption material of the present invention has high separation performance, it can be used in the process of recovering the active ingredients of biopharmaceuticals from the biopharmaceutical raw material solution in the process of purifying biopharmaceuticals from the biopharmaceutical raw material solution.
- the biopharmaceutical is an antibody drug
- antibody loss also occurs in subsequent steps. Therefore, it is preferable that the antibody recovery rate after treating the biopharmaceutical raw material solution using a porous adsorbent material is as high as possible. Specifically, the antibody recovery rate is preferably 85% or higher, more preferably 90% or higher.
- the residual rate of HCP after the biopharmaceutical raw material solution is treated using a porous adsorption material is as low as possible. Specifically, it is preferably 60% or less, more preferably 50% or less, and even more preferably 40% or less.
- the separation ratio obtained by dividing the antibody recovery rate by the HCP residual rate is an index of the separation selectivity of the porous adsorbent material. The separation ratio is preferably 1.5 or higher, more preferably 1.8 or higher, and even more preferably 2 or higher.
- the methods shown in the Examples can be used.
- the process of recovering and separating antibodies from biopharmaceutical raw material solutions in the manufacturing process of antibody proteins used as antibody drugs which are one of biopharmaceuticals, such as monoclonal antibodies, polyclonal antibodies, humanized antibodies, human antibodies, and immunoglobulins.
- biopharmaceuticals such as monoclonal antibodies, polyclonal antibodies, humanized antibodies, human antibodies, and immunoglobulins.
- the protein-adsorbing material of the present invention is used in the pretreatment step of the antibody recovery step using a protein A column, excessive adsorption of antibodies to the protein-adsorbing material leads to antibody loss, so the amount of antibody adsorption is 100 mg / m 2 or less is preferred.
- the adsorption amount of HCP is preferably 100 mg/m 2 or more.
- the protein adsorption ratio obtained by dividing the adsorption amount of HCP by the adsorption amount of the antibody is a protein adsorption material with high purification efficiency. It can be said that it is an indicator of The protein adsorption ratio is preferably 2 or more.
- the porous adsorbent material or protein adsorbent material of the present invention has an antibody adsorption amount of 100 mg/m 2 or less and a separation ratio of 1.5 or more, which is useful for culturing antibody-producing cells. It is very useful as a material for adsorbing and removing HCP, which is a contaminant, from a clean liquid.
- the separation ratio is more preferably 1.0 or higher, more preferably 2.0 or higher.
- the amount of HCP per amount of antibody which is an index of HCP removal efficiency, reaches a level of several tens of ppm, which is regarded as no problem when it is transferred to downstream processes such as ion chromatography. .
- the antibody adsorption amount is within the above range, clogging of the adsorption material can be prevented.
- a PMMA solid fiber having pores with an average pore radius of 5 nm is mixed with a vinylpyrrolidone/vinyl propanoate random copolymer (mol fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000). It was immersed in an aqueous solution dissolved so as to have a concentration of 100 ppm and an ethanol concentration of 500 ppm, and was irradiated with ⁇ - rays of 25 kGy. , 6.75 mL of culture supernatant obtained from Chinese hamster ovary (CHO) cells (antibody concentration 3.63 mg/mL, HCP concentration 1.46 mg/mL) was added, covered, and shaken at room temperature for 6 hours.
- CHO Chinese hamster ovary
- Culture supernatants are sampled and antibody concentrations in the culture supernatants are measured using immunoturbidimetry.
- the HCP concentration in the culture supernatant is measured by ELISA using CHO Host Cell Proteins 3rd Generation (manufactured by Cygnus Technologies).
- the antibody adsorption amount, the HCP adsorption amount, and the protein adsorption ratio are calculated by the following formulas.
- Protein adsorption ratio HCP adsorption amount/antibody adsorption amount.
- the adsorbed amount of antibody larger than the pore size was 66 mg/m 2
- the adsorbed amount of HCP smaller than the pore size was 148 mg/m 2
- the protein adsorption ratio was 2.24.
- the adsorption amount of proteins not to be adsorbed is 100 mg/m 2 or less
- the adsorption amount of HCP is 100 mg/m 2 or more
- the protein adsorption ratio is 2 or more, which is larger than the pore size of the protein adsorption material of the present invention.
- it can be applied to the step of recovering antibodies in the manufacturing process of antibody drugs, which is preferable.
- the antibody recovery rate was 92%
- the HCP residual rate was 55%
- the separation ratio was 1.7. It can be understood that it is excellent as
- the above material has a separation ratio of 1.7 and an antibody adsorption amount of 66 mg/m 2 , so it is useful as a material for adsorbing and removing contaminants, HCP, from the culture supernatant of antibody-producing cells. I can say there is.
- the manufacturing process of general antibody drugs consists of the process of culturing cells that produce antibodies, the process of separating cells and antibodies, the antibody recovery and purification process, the virus inactivation process, and the virus removal process.
- a centrifugation method or a depth filtration method is used in the step of separating cells and antibodies.
- a protein A column on which protein A that specifically adsorbs the antibody is immobilized is mainly used for recovery of the antibody.
- an anion exchange column or a cation exchange column is used to remove the animal cell-derived protein (HCP) used for antibody production.
- HCP animal cell-derived protein
- treatment at a low pH of pH 4 or less is common.
- the biopharmaceutical raw material solution contains antibody aggregates and degradation products as contaminants.
- the molecular weight of the degradation product of the antibody is mainly in the range of 10 kDa to 110 kDa, depending on the sites subjected to degradation, and is close to the molecular weight distribution of HCP, so it can be adsorbed and removed by the porous adsorption material of the present invention. Therefore, the porous adsorption material of the present invention can adsorb degradation products of antibodies other than antibodies, which are the main components of antibody drugs, which are difficult to adsorb and remove with a protein A column, so it is safer with less contaminants. It is possible to provide antibody drugs that are
- the porous adsorbent material of the present invention does not use an antibody-binding ligand such as protein A, there is no possibility that protein A will be contained in the final antibody drug, thereby providing a safe antibody drug with few side effects. be able to.
- the separation column for biopharmaceutical purification of the present invention incorporates the porous adsorption material of the present invention.
- the shape of the casing of the separation column for purifying biopharmaceuticals of the present invention is open at both ends, and includes, for example, rectangular cylinders such as square cylinders and hexagonal cylinders, and cylindrical bodies.
- a perfectly circular cylinder is preferred. This is because the casing has no corners, so that blood can be prevented from stagnation at the corners.
- the casing is a device made of plastic, metal, or the like. Among them, plastic is preferably used from the viewpoint of cost, moldability, weight, and the like.
- thermoplastic resins that are excellent in mechanical strength and thermal stability are used.
- thermoplastic resins include polycarbonate-based resins, polyvinyl alcohol-based resins, cellulose-based resins, polyester-based resins, polyarylate-based resins, polyimide-based resins, cyclic polyolefin-based resins, polysulfone-based resins, and polyethersulfone.
- polypropylene, polystyrene, polycarbonate and derivatives thereof are preferred in view of moldability and radiation resistance required for the casing. This is because resins with excellent radiation resistance are preferable when radiation is applied during sterilization.
- Resin is manufactured by injection molding using a mold or by cutting a material.
- the porous adsorption material of the present invention is built into the separation column for purification of biopharmaceuticals of the present invention
- the porous adsorption material is preferably arranged in a straight shape. This is because the liquid to be treated flows along the porous adsorbent material, which makes it difficult for turbulence to occur, and facilitates uniform distribution of the liquid to be treated in the column.
- the method for producing a biopharmaceutical of the present invention includes a step of preparing a biopharmaceutical raw material solution and a step of bringing the biopharmaceutical raw material solution into contact with a porous adsorption material.
- the method for producing a biopharmaceutical of the present invention may include a purification method other than the step of preparing a biopharmaceutical raw material solution and the step of bringing the biopharmaceutical raw material solution into contact with a porous adsorption material.
- Other purification methods are not particularly limited as long as they are suitable for the production of pharmaceuticals. Examples include chromatography (e.g., anion exchange chromatography, cation exchange chromatography, and mixed chromatography), Examples include virus inactivation, virus removal, and the like.
- a porous adsorption material for adsorbing and removing contaminants from a biopharmaceutical raw material solution and a porous hollow fiber membrane for separating and removing contaminants are prepared, and the biopharmaceutical raw material solution is prepared as described above.
- the porous adsorption material and the porous hollow fiber membrane are continuously treated.
- the manner in which the porous adsorption material and the porous hollow fiber membrane are housed is not particularly limited. It is preferable to adopt a column or module mode incorporating the porous adsorption material or the porous hollow fiber membrane.
- the term “continuously” refers to an outlet through which a purified solution is discharged from a column or module containing the porous adsorption material or the porous hollow fiber membrane, and the following porous hollow fiber membrane or porous adsorption It means that the module or column containing the material is in communication.
- a module or column containing another porous hollow fiber membrane or porous adsorbent material It may be in such a manner that the treated liquid from the column is merged, or from between the module or column containing the porous hollow fiber membrane and the module or column containing the porous adsorbent material, other
- the treatment liquid may be branched into a module or column containing a porous hollow fiber membrane or porous adsorbent material.
- the order of treatment of the porous adsorbent material or the porous hollow fiber membrane is not particularly limited. Since the separation performance of the porous hollow fiber membrane is affected, it is preferable to perform the separation using the porous hollow fiber membrane first.
- the module containing the porous hollow fiber membrane may have a multistage configuration. That is, a plurality of the modules are arranged, the filtrate outlet of the preceding module is connected to the latter module, and the treated liquid is sequentially sent to the multi-stage modules for repeated separation.
- the multistage arrangement improves the recovery rate of substances larger than the pore diameter of the porous hollow fiber membrane.
- Methods for flowing the biopharmaceutical raw material solution through the porous hollow fiber membrane include a total filtration method in which the entire biopharmaceutical raw material solution is passed through the membrane and the biopharmaceutical remaining on the membrane is recovered by washing; While the biopharmaceutical raw material solution is circulated multiple times to purify the biopharmaceutical, the cross-flow method is preferable from the viewpoint of improving the recovery rate without leaving the biopharmaceutical on the membrane.
- porous adsorbent material An example of producing the porous adsorbent material according to the present invention will be described below with reference to an example of producing a protein adsorbent material, which is a representative example.
- a spinning stock solution is prepared by dissolving a polymer in a solvent.
- the concentration of the stock solution the concentration of the substance in the stock solution excluding the solvent
- the concentration of the stock solution in the present invention is preferably 30% by mass or less, more preferably 27% by mass or less, and even more preferably 24% by mass or less.
- the proportion of the polymer having methacrylsulfonic acid-p-styrenesulfonic acid in the total polymer is preferably 10 mol % or less.
- the lower limit of the stock solution viscosity is 10 poise or more, more preferably 90 poise or more, still more preferably 400 poise or more, and particularly preferably 800 poise or more.
- the upper limit of the stock solution viscosity at the temperature of the spinneret is 100,000 poise or less, more preferably 50,000 poise or less.
- the fibers are obtained by ejecting the undiluted solution from the spinneret, passing it through a dry air section at a certain distance, and then ejecting it into a coagulation bath consisting of a poor solvent such as water or a non-solvent.
- the shape of the cross section of the fiber is not particularly limited, but when using a fiber with an irregular cross section as the protein adsorption material, it is preferable to mix it with a circular or elliptical fiber.
- the post-mixing method includes a method of supplying fibers to the washing process and the winding process of spinning and mixing them, a method of mixing by air entangling, a method of mixing by twisting, doubling, and aligning, and a method of mixing by weaving. Examples include, but are not limited to, a method of mixing, a method of mixing by knitting, and a method of dispersing and collecting in a liquid. Moreover, composite spinning is mentioned as a spinning mixed fiber method.
- Composite spinning involves the method of simultaneously discharging and winding multiple yarns from the same spinneret with multiple discharge holes, or using a monohole spinneret to mix spinnerets with different discharge port shapes in a spinneret discharge block.
- post-mixing is more likely to cause partial bias than the spinning and mixing method, and when looking at the state of the cross section of the fiber, partial bias may occur, and the quality stability as a fiber has a problem.
- unevenness is less likely to occur and the quality can be stabilized, which is preferable.
- Additives and the like may be added as long as they do not interfere with the actions and effects of the present invention.
- the dry part refers to the part where the spinning dope runs idle from the time it is discharged from the spinneret until it comes into contact with the poor solvent, or until the structure is completely fixed by cooling.
- the spinning dope is structurally fixed, the vicinity of the surface of the dope is in a state of high energy. Therefore, it is believed that the fiber surface is formed by aggregation of the supporting component such as the polymer upon contact with the poor solvent or moisture contained in the air. Therefore, it is necessary that the porous structure is determined to some extent before the spinning dope comes into contact with the poor solvent, that is, in the dry part.
- the residence time is 0.05 seconds or more, preferably 0.20 seconds or more, and more preferably 0.40 seconds or more. The residence time is calculated from the following formula.
- Residence time (seconds) dry length (m)/winding speed (m/second)
- seconds dry length (m)/winding speed (m/second)
- the spinning dope discharged from the spinneret is coagulated in a coagulation bath.
- the coagulation bath usually consists of a coagulant such as water or alcohol, or a mixture with a solvent that constitutes the spinning dope.
- the pore size can be varied by controlling the temperature of the coagulation bath. Since the pore size can be affected by the type of spinning dope, etc., the temperature of the coagulation bath is also appropriately selected. Generally, the pore size can be increased by increasing the coagulation bath temperature. Although the exact mechanism is not clear, it is thought that the solvent removal from the stock solution and the solidification shrinkage are competing with each other. be done. However, if the temperature of the coagulation bath becomes too high, the pore size becomes excessively large, which may have effects such as a decrease in specific surface area, a decrease in strength and elongation, and an increase in non-specific adsorption.
- the coagulation bath temperature is preferably 90° C. or lower, more preferably 75° C. or lower, and particularly preferably 65° C. or lower.
- the lower limit is preferably 12° C. or higher, more preferably 20° C. or higher.
- the fibers are then washed to remove the solvent adhering to the coagulated fibers.
- the means for washing the fibers is not particularly limited, but a preferred method is to pass the fibers through a bath filled with water in multiple stages (referred to as a washing bath).
- the temperature of the water in the washing bath may be determined according to the properties of the polymer that constitutes the fiber. For example, in the case of fibers containing PMMA, 30 to 50°C is adopted.
- a step of applying a moisturizing component to the fibers may be added.
- moisturizing component refers to a component capable of maintaining the humidity of the fiber, or a component capable of preventing a decrease in the humidity of the fiber in the air.
- moisturizing ingredients include glycerin and its aqueous solution.
- the heat treatment bath is filled with a heated aqueous solution of moisturizing ingredients, and when the fibers pass through this heat treatment bath, they are subjected to thermal action and shrink. can be stabilized.
- the heat treatment temperature at this time varies depending on the fiber material, but in the case of fibers containing PMMA, it is preferably 50° C. or higher, more preferably 80° C. or higher. Moreover, 95 degrees C or less is preferable and 87 degrees C or less is set as a more preferable temperature.
- the method for producing a separation column for biopharmaceutical purification using the obtained porous adsorption material is not particularly limited, but an example is as follows. First, the porous adsorbent material is cut to a required length and placed in a casing so as to be straight in the axial direction of the casing. After that, both ends of the porous adsorbent material are cut with a cutter or the like so that the porous adsorbent material fits inside the casing, and a mesh filter cut to the same diameter as the inner diameter is attached to the inlet/outlet of the liquid to be treated on both side end faces of the column. Finally, an inlet port and an outlet port for the liquid to be treated, called header caps, are attached to both ends of the casing to obtain a separation column for biopharmaceutical purification.
- TOF-SIMS measurement (measurement of thickness of layer containing nonionic polymer or biocomponent adhesion inhibitory polymer) A sample (one fiber) was embedded in resin and a cross section was prepared using a microtome. TOF. It was measured under the following conditions using SIMS5 (manufactured by ION-TOF).
- the vinylpyrrolidone/vinylpropanoate random copolymer (mol fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000), vinylpyrrolidone/vinyl hexanoate, and vinylpyrrolidone/vinyl hexanoate used in the following examples
- Random copolymer (mol fraction of vinyl hexanoate unit: 40%, number average molecular weight: 68,000)
- vinylpyrrolidone/vinyl propanoate random copolymer (mol fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000)
- the polymer having a molecular weight of 100,000) corresponds to the biocomponent adhesion-inhibiting polymer referred to in the present invention, and is a nonionic polymer.
- Average pore radius [nm] (33.30 ⁇ 0.3181 ⁇ melting point depression amount [° C.])/melting point DSC Q1001 manufactured by TA Instruments was used as a measuring apparatus.
- the amount of melting point depression is the difference obtained by subtracting the peak top temperature of the curve from the melting point of water (0°C).
- the visual field A field of view of 640 ⁇ 480 pixels that completely encompasses 1 was taken as near-surface.
- the field of view of 640 ⁇ 480 pixels that completely encompasses the field of view 2 and does not include the field of view 1 was defined as the near surface.
- the center of the straight line having the longest length was taken as the central portion. Assuming that the pores are perfect circles, the pore radius was calculated from the pore area by the following formula.
- Pore radius at the center or near the surface [nm] (Pore area at the center or near the surface [nm 2 ]/ ⁇ ) 1/2
- the pore radius was obtained by measuring the center and near the surface of the cross section obtained by cutting the sample at any five points, and the average value was determined as the average pore diameter at the center or near the surface.
- the ratio of the average pore size in the center to the average pore size in the vicinity of the surface was calculated by the following equation.
- the ratio of the average pore size in the center to the average pore size in the vicinity of the surface average pore size in the center/average pore size in the vicinity of the surface.
- Antibody concentration was measured using immunoturbidimetry.
- the HCP concentration was measured by ELISA using CHO Host Cell Proteins 3rd Generation (manufactured by Cygnus Technologies).
- Antibody adsorption amount, HCP adsorption amount, antibody recovery rate, HCP residual rate, protein adsorption ratio, and separation ratio were calculated by the following equations.
- the antibody concentration before adsorption of the culture supernatant used was 3.63 mg/mL, and the HCP
- Antibody and HCP adsorption amount, protein adsorption ratio, and separation ratio were used as indicators of adsorption performance.
- the amount of adsorption of the target antibody is low, while the amount of adsorption of impurities typified by HCP is high. Therefore, the antibody adsorption amount, the HCP adsorption amount, the protein adsorption ratio obtained by dividing the HCP adsorption amount by the antibody adsorption amount, and the separation ratio obtained by dividing the antibody recovery rate by the HCP residual rate are the purification efficiency. It can be said to be an indicator of a high protein adsorption material.
- Example 1 [Production of Protein Adsorbing Material Having Pores] 31.7 parts by weight of syn-PMMA with a weight average molecular weight of 400,000, 31.7 parts by weight of syn-PMMA with a weight average molecular weight of 1.4 million, and 16.7 parts by weight of iso-PMMA with a weight average molecular weight of 500,000 20 parts by mass of a PMMA copolymer having a molecular weight of 300,000 and containing 1.5 mol % of sodium p-styrenesulfonate was mixed with 376 parts by mass of dimethylsulfoxide and stirred at 110°C for 8 hours to prepare a spinning dope.
- Production Example 1 was measured with an electronic balance and washed 10 times while exchanging pure water. After removing the moisture on paper towels, it was placed in a lidded plastic tube. An aqueous solution of vinylpyrrolidone/vinyl propanoate random copolymer (mol fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) dissolved to a concentration of 50 ppm and an ethanol concentration of 500 ppm was added to a plastic tube, It was irradiated with 25 kGy of ⁇ -rays. After ⁇ -ray irradiation, the aqueous copolymer solution was removed, and the substrate was washed 10 times while exchanging pure water. This is referred to as Example 1.
- Example 1 the thickness of the layer containing the biocomponent adhesion-inhibiting polymer (layer containing the biocomponent adhesion-inhibiting polymer), the ratio of nitrogen atoms to the total atoms 100 (atom number %), the average pore radius, and the average pore diameter and adsorption performance were measured by the method described above. Table 1 shows the results.
- Example 2 The same treatment as in Example 1, except that the concentration of the vinylpyrrolidone/vinyl propanoate random copolymer of Example 1 (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was changed to 100 ppm. did This is referred to as Example 2. Table 1 shows the results.
- Example 3 The same treatment as in Example 1, except that the concentration of the vinylpyrrolidone/vinyl propanoate random copolymer of Example 1 (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was changed to 200 ppm. did This is referred to as Example 3. Table 1 shows the results.
- Example 4 Instead of the aqueous solution of Example 1, in which the vinylpyrrolidone/vinyl propanoate random copolymer (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was dissolved so as to have a concentration of 100 ppm and an ethanol concentration of 500 ppm. 2, vinyl pyrrolidone/vinyl hexanoate random copolymer (molar fraction of vinyl hexanoate unit: 40%, number average molecular weight: 68,000) was dissolved in an aqueous solution with a concentration of 200 ppm and an ethanol concentration of 500 ppm. Except for this, the same treatment as in Example 1 was performed. This is referred to as Example 4. Table 1 shows the results.
- Example 5 Instead of the aqueous solution of Example 1, in which the vinylpyrrolidone/vinyl propanoate random copolymer (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was dissolved so as to have a concentration of 100 ppm and an ethanol concentration of 500 ppm. 2, vinyl pyrrolidone/vinyl propanoate random copolymer (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 100,000) was dissolved in an aqueous solution with a concentration of 100 ppm and an ethanol concentration of 500 ppm. Except for this, the same treatment as in Example 1 was performed. This is referred to as Example 5. Table 1 shows the results.
- Example 6 The same treatment as in Example 1, except that the concentration of the vinylpyrrolidone/vinyl propanoate random copolymer of Example 1 (mol fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was changed to 10 ppm. did This is referred to as Example 6. Table 1 shows the results.
- Example 7 Same as Example 1, except that the concentration of the vinylpyrrolidone/vinyl propanoate random copolymer of Example 1 (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was 1,000 ppm. was processed. This is referred to as Example 7. Table 1 shows the results.
- Comparative example 1 Instead of the aqueous solution of Example 1, in which the vinylpyrrolidone/vinyl propanoate random copolymer (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was dissolved so as to have a concentration of 100 ppm and an ethanol concentration of 500 ppm. The same treatment as in Example 1 was carried out, except that pure water was used for . This is referred to as Comparative Example 1. Table 1 shows the results. The separation ratio is 1.9, which satisfies the preferred range, but the antibody adsorption amount is 100 mg/m 2 or more, which does not satisfy the preferred range. It can be said that the performance as a material for adsorbing and removing HCP is insufficient.
- Comparative example 2 Instead of the aqueous solution in which the vinylpyrrolidone/vinyl propanoate random copolymer of Example 1 (molar fraction of vinyl propanoate unit: 40%, number average molecular weight: 68,000) was dissolved so as to have a concentration of 100 ppm and an ethanol concentration of 500 ppm , and polyethylenimine (molecular weight: 750,000) dissolved in an aqueous solution having a concentration of 100 ppm were used. This is referred to as Comparative Example 2. Table 1 shows the results.
- the porous adsorption material of the present invention can adsorb target proteins while suppressing clogging caused by proteins that are not targets of adsorption, and therefore can be suitably used as a material for separating and purifying proteins, which are target substances. .
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
なお、上記測定方法は、Kazuhiro Ishikiriyama et al.;JOURNAL OF COLLOID AND INTERFACE SCIENCE,171,103-111,(1995)の記載を参考としている。
多孔質吸着材料、あるいは、タンパク質吸着材料を任意の5箇所で切断した断面の中心部および表面近傍でそれぞれ測定を行い、細孔半径を求め、その平均値を求めて中心部または表面近傍の平均孔径とする。
HCP吸着量(mg/m2)=(吸着前(HCP濃度×液量)-吸着後(HCP濃度×液量))÷0.03
タンパク質の吸着比率=HCP吸着量÷抗体吸着量 。
ポリマーを溶媒に溶かした紡糸原液を調整する。このとき原液濃度(原液中の溶媒を除いた物質の濃度)が低い程、繊維の孔径を大きくすることが出来るため、原液濃度を適宜設定することにより、孔径・細孔量をコントロールすることが可能である。この他、陰性荷電基を有するポリマーを用いることでも孔径・細孔量のコントロールが可能である。かかる観点から、本発明において好ましい原液濃度は30質量%以下であり、より好ましくは27質量%以下、さらに好ましくは24質量%以下である。また、陰性荷電基として、例えばメタクリルスルホン酸パラスチレンスルホン酸を有するポリマーを用いる場合、全ポリマー中に存在するメタクリルスルホン酸パラスチレンスルホン酸を有するポリマーの割合は10mol%以下であることが好ましい。
また、吐出した繊維の温度が乾式部において低下してゲル化や凝固するなど速やかに構造固定化される場合には、乾式部分において冷風を吹き付け、ゲル化を促進させることができる。また、詳細なメカニズムは定かではないが冷風速度を上げて冷却効率を上げることで、繊維表面の開孔率や繊維外周部近傍の孔径を拡大させることができる。口金から吐出された紡糸原液は凝固浴にて凝固される。凝固浴は通常、水やアルコールなどの凝固剤、または紡糸原液を構成している溶媒との混合物からなる。通常は水を用いることが多い。また、凝固浴の温度をコントロールすることにより、孔径を変化させることができる。孔径は紡糸原液の種類等によって影響を受け得るために、凝固浴の温度も適宜選択される。一般に凝固浴温度を高くすることにより、孔径を大きくすることが出来る。この機序は正確には明らかではないが、原液からの脱溶媒と凝固収縮との競争反応により、高温浴では脱溶媒が速く、繊維内部が収縮する前に凝固固定されるからではないかと考えられる。しかしながら、凝固浴温度が高くなりすぎると、孔径が過大になるため、比表面積の低下、強伸度の低下、非特異的な吸着などが増大する、などの影響が考えられる。そのため、例えば、繊維がPMMAを含む場合の凝固浴温度は90℃以下が好ましく、より好ましくは75℃以下、特に好ましくは65℃以下である。一方で、凝固温度が低すぎる場合、孔径が縮小し、被吸着物質が細孔内部に拡散しにくくなる。そのため下限としては12℃以上が好ましく、20℃以上がより好ましい。
試料(繊維1本)を樹脂に包埋し、ミクロトームを用いて断面を作製した。TOF.SIMS5(ION-TOF社製)を用いて以下の条件で測定した。
一次イオン: Bi3++
一次イオン加速電圧: 25kV
パルス幅: 125.0ns
二次イオン極性: 負
スキャン数: 96scan
Cycle time: 200μs
ラスターサイズ: 50×50μm2
質量範囲(m/z): 0~1500
<層厚みの測定1>
得られた質量m/zのスペクトルから、中実繊維断面の任意の3箇所についてラインプロファイルを作製し、生体成分付着抑制ポリマーを含む層の厚みを有効数字2桁で算出した。3箇所の平均値を、生体成分付着抑制ポリマーを含む層の厚みとした。
得られた質量m/zのスペクトルから、中実繊維断面の任意の1箇所についてラインプロファイルを作製し、生体成分付着抑制ポリマーを示すCN-+CNO-のプロファイルが平坦にみえる箇所に線を引き、当該線が生体成分付着抑制ポリマーのピーク両端と交わる2点の間隔を、生体成分付着抑制ポリマーを含む層の厚みとし、有効数字2桁で表した。
試料を超純水でリンスした後、室温、0.5Torrにて10時間乾燥させ、測定に供した。
装置 :Quantera SXM(PHI社製)
励起X線 :monochromaticAlKα1,2線(1486.6eV)
X線径 :100μm
光電子検出角度:45°(試料表面に対する検出器の傾き)
窒素原子量としては、N1sの400eV付近に現れるピークの面積から、全元素(水素原子は検出できないので、水素原子以外の全元素)に対する該ピーク面積の割合を算出し、窒素原子量(原子数%)を求めた。
示差走査熱量計(DSC)を用いた示差走査熱量(DSC)測定により、細孔内の水の毛管凝集による氷点降下度を測ることで求めた。すなわち、試料を-55℃に急冷し、5℃まで0.3℃/minで昇温させて測定し、得られた曲線のピークトップ温度を融点として、次式から平均細孔半径を算出した。
測定装置は、TA Instruments社製 DSC Q1001を用いた。
走査型電子顕微鏡(SEM)(S-5500、株式会社日立ハイテクノロジー社製)で試料の表面を観察し、画像解析を行った。SEMを用いて倍率50,000倍で観察し、640×480pixelsの画像を、画像処理ソフト(ImageJ、開発元 アメリカ国立衛生研究所)にて二値化処理し、細孔部分が黒、構造ポリマー部分が白となった画像を得た。
試料を任意の5箇所で切断した断面の中心部および表面近傍でそれぞれ測定を行って細孔半径を求め、その平均値を求めて中心部または表面近傍の平均孔径とした。次式により表面近傍の平均孔径に対する中心部の平均孔径の比を算出した。
試料を膜面積が0.03m2となるよう片刃カミソリを用いて採取し、ペーパータオル上で水分を除去したのち、フタ付きプラスチック製チューブに入れた。0.6Nの塩酸を添加してpH7.4に調整したCHO細胞由来培養上清(以下、「培養上清」)の6.75mLを添加してフタをし、シーソーシェイカー(TAITEC社製)を用いて室温にて振とう攪拌した。培養上清添加から6時間後に培養上清をサンプリングし、培養上清中の抗体濃度およびHCP濃度を測定した。
HCP吸着量(mg/m2)=(吸着前(HCP濃度×液量)-吸着後(HCP濃度×液量))÷0.03
タンパク質の吸着比率=HCP吸着量÷抗体吸着量
抗体回収率(%)=(吸着後(抗体濃度×液量)÷吸着前(抗体濃度×液量))×100
HCP残存率(%)=(吸着後(HCP濃度×液量)÷吸着前(HCP濃度×液量))×100
分離比率=抗体回収率÷HCP残存率
なお、使用した培養上清の吸着前の抗体濃度は3.63mg/mL、HCP濃度は1.46mg/mLであった。
[細孔を有するタンパク質吸着材料の製造]
質量平均分子量が40万のsyn-PMMAを31.7質量部、質量平均分子量が140万のsyn-PMMAを31.7質量部、質量平均分子量が50万のiso-PMMAを16.7質量部、パラスチレンスルホン酸ソーダを1.5mol%含む分子量30万のPMMA共重合体20質量部をジメチルスルホキシド376質量部と混合し、110℃で8時間撹拌し紡糸原液を調製した。得られた紡糸原液を、92℃に保温された十字形状および楕円形状の口金(口金比率=17:7)から、1.1g/minの速度で空気中に吐出し、空中部分を380mm走行させた後、凝固浴に導き、浴内を通過させて十字形および楕円形の中実繊維を得た。凝固浴には水を用いており、水温(凝固浴温度)は42℃であった。繊維を水洗後、保湿剤としてグリセリンを70質量%含む水溶液から成る浴槽に導いた後、温度を84℃とした熱処理浴内を通過させて余分のグリセリンを除去した後に16m/minで巻き取った。これを製造例1とした。
実施例1のビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)の濃度を100ppmとした点を除き、実施例1と同様の処理を行った。これを実施例2とした。結果を表1に示した。
実施例1のビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)の濃度を200ppmとした点を除き、実施例1と同様の処理を行った。これを実施例3とした。結果を表1に示した。
実施例1の、ビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)を濃度100ppm、エタノール濃度500ppmとなるように溶解した水溶液の代わりに、ビニルピロリドン/ヘキサン酸ビニルランダム共重合体(ヘキサン酸ビニルユニットのモル分率40%、数平均分子量68,000)を濃度200ppm、エタノール濃度500ppmとなるように溶解した水溶液を用いた点を除き、実施例1と同様の処理を行った。これを実施例4とした。結果を表1に示した。
実施例1の、ビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)を濃度100ppm、エタノール濃度500ppmとなるように溶解した水溶液の代わりに、ビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量100,000)を濃度100ppm、エタノール濃度500ppmとなるように溶解した水溶液を用いた点を除き、実施例1と同様の処理を行った。これを実施例5とした。結果を表1に示した。
実施例1のビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)の濃度を10ppmとした点を除き、実施例1と同様の処理を行った。これを実施例6とした。結果を表1に示した。
実施例1のビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)の濃度を1,000ppmとした点を除き、実施例1と同様の処理を行った。これを実施例7とした。結果を表1に示した。
実施例1の、ビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)を濃度100ppm、エタノール濃度500ppmとなるように溶解した水溶液の代わりに純水を用いた点を除き、実施例1と同様の処理を行った。これを比較例1とした。結果を表1に示した。分離比率は1.9であり好ましい範囲を満たしているが、抗体吸着量は100mg/m2以上であり好ましい範囲を満たしておらず、比較例1は抗体産生細胞の培養上清から、夾雑物であるHCPを吸着除去するための材料としての性能が不十分であると言える。
実施例1のビニルピロリドン/プロパン酸ビニルランダム共重合体(プロパン酸ビニルユニットのモル分率40%、数平均分子量68,000)を濃度100ppm、エタノール濃度500ppmとなるように溶解した水溶液の代わりに、ポリエチレンイミン(分子量75万)を濃度100ppmとなるように溶解した水溶液を用いた点を除き、実施例1と同様の処理を行った。これを比較例2とした。結果を表1に示した。
Claims (14)
- バイオ医薬品原料溶液から夾雑物を吸着除去するために用いる多孔質吸着材料であって、その少なくとも一方の表面にノニオン性ポリマーを含む層を有する多孔質吸着材料。
- 前記夾雑物は、タンパク質であり、前記ノニオン性ポリマーは、生体成分付着抑制ポリマーであり、かつ、飛行時間型二次イオン質量分析法(TOF-SIMS)にて組成分析した際の前記生体成分付着抑制ポリマーを含む層の下記の方法で求められる層の厚みが3μm以下である請求項1に記載の多孔質吸着材料。
<層厚みの測定1>
得られた質量m/zのスペクトルから、多孔質吸着材料断面の任意の3箇所についてラインプロファイルを作製し、生体成分付着抑制ポリマーを含む層の厚みを3箇所の平均値として求める。 - 前記ノニオン性ポリマーを含む層の飛行時間型二次イオン質量分析法(TOF-SIMS)にて組成分析した際の前記ノニオン性ポリマーを含む層の下記の方法で求められる厚みが、1.5μm以上、5μm以下である、請求項1記載の多孔質吸着材料。
<層厚みの測定2>
得られた質量m/zのスペクトルから、多孔質吸着材料断面の任意の1箇所についてラインプロファイルを作製し、ノニオン性ポリマーに特徴的なイオン種に着眼してそのプロファイルが平坦にみえる箇所に線を引き、当該線がノニオン性ポリマーに由来するピーク両端と交わる2点の間隔を、ノニオン性ポリマーを含む層の厚みとして求める。 - 前記多孔質吸着材料について、示差走査熱量計(DSC)で測定される平均細孔半径が1nm以上100nm以下であり、比表面積が0.05m2/g以上、0.5m2/g以下である請求項1から3のいずれかに記載の多孔質吸着材料。
- 前記多孔質吸着材料が繊維形状である請求項1~4のいずれかに記載の多孔質吸着材料。
- 前記ノニオン性ポリマーが疎水性ユニットと親水性ユニットを有する共重合ポリマーである、請求項1~5のいずれかに記載の多孔質吸着材料。
- 前記疎水性ユニットがモノカルボン酸ビニルエステルユニットである、請求項6に記載の多孔質吸着材料。
- 前記ノニオン性ポリマーが、さらにビニルピロリドンユニットを有する請求項7に記載の多孔質吸着材料。
- 前記モノカルボン酸ビニルエステルユニットが、「-CH(OCO-R)-CH2-」(ここで、Rは炭素数2~5の脂肪族炭化水素基)である請求項7または8に記載の多孔質吸着材料。
- 前記多孔質吸着材料は、抗体と宿主由来タンパク質(HCP)を含む溶液からHCPを選択的に吸着するものである請求項1~8のいずれかに記載の多孔質吸着材料。
- 抗体とHCPの分離比率が1.5以上である請求項10に記載の多孔質吸着材料。
- 請求項1~11のいずれかに記載の多孔質吸着材料を内蔵しているバイオ医薬品精製用分離カラム。
- バイオ医薬品原料溶液を準備する工程と、請求項1~11のいずれかに記載の多孔質吸着材料にバイオ医薬品原料溶液を接触せしめる工程とを含む、バイオ医薬品の製造方法。
- 多孔質中空糸膜と請求項1~11のいずれかに記載の多孔質吸着材料とが連続的に配置され、それぞれで夾雑物の分離・除去を行うことを特徴とする、請求項13記載のバイオ医薬品の製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22775391.0A EP4316646A1 (en) | 2021-03-26 | 2022-03-17 | Porous adsorbent material, separation column using same for purifying biopharmaceutical, and method for manufacturing biopharmaceutical |
JP2022525275A JPWO2022202603A1 (ja) | 2021-03-26 | 2022-03-17 | |
CN202280024522.8A CN117177812A (zh) | 2021-03-26 | 2022-03-17 | 多孔吸附材料和使用其的生物药品精制用分离柱、以及生物药品的制造方法 |
US18/283,231 US20240173692A1 (en) | 2021-03-26 | 2022-03-17 | Porous adsorbent material, separation column using same for purifying biopharmaceutical, and method of manufacturing biopharmaceutical |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-052834 | 2021-03-26 | ||
JP2021052834 | 2021-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022202603A1 true WO2022202603A1 (ja) | 2022-09-29 |
Family
ID=83395771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/012248 WO2022202603A1 (ja) | 2021-03-26 | 2022-03-17 | 多孔質吸着材料、およびそれを用いたバイオ医薬品精製用分離カラム、ならびに、バイオ医薬品の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240173692A1 (ja) |
EP (1) | EP4316646A1 (ja) |
JP (1) | JPWO2022202603A1 (ja) |
CN (1) | CN117177812A (ja) |
WO (1) | WO2022202603A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07509173A (ja) * | 1992-06-19 | 1995-10-12 | セプラコア インコーポレーテッド | 表面処理および安定化した多孔質支持体,その製造法ならびに使用法 |
JP2012224729A (ja) * | 2011-04-19 | 2012-11-15 | Asahi Kasei Medical Co Ltd | グラフト鎖を導入する方法、多孔質吸着膜、及びタンパク質の精製方法 |
JP5420341B2 (ja) | 2009-08-04 | 2014-02-19 | 日機装株式会社 | 血球除去用吸着体及びその製造方法 |
JP2014207989A (ja) | 2013-03-29 | 2014-11-06 | 東レ株式会社 | タンパク質吸着材料およびその製造方法、血液浄化器 |
WO2016067967A1 (ja) | 2014-10-28 | 2016-05-06 | 東レ株式会社 | 多孔質繊維、吸着材料及び浄化カラム |
WO2016175306A1 (ja) * | 2015-04-30 | 2016-11-03 | 昭和電工株式会社 | タンパク質の精製方法 |
WO2017090658A1 (ja) * | 2015-11-24 | 2017-06-01 | Jsr株式会社 | 多孔質粒子の製造方法、多孔質粒子、担体、カラム、及び標的物質の分離方法 |
JP2019166520A (ja) * | 2018-03-23 | 2019-10-03 | 東レ株式会社 | バイオ医薬品精製システム |
WO2019225730A1 (ja) | 2018-05-24 | 2019-11-28 | 東レ株式会社 | 多孔質中空糸膜 |
JP2020006155A (ja) | 2018-07-02 | 2020-01-16 | 旭化成メディカル株式会社 | 血液処理用ビーズ |
-
2022
- 2022-03-17 CN CN202280024522.8A patent/CN117177812A/zh active Pending
- 2022-03-17 EP EP22775391.0A patent/EP4316646A1/en active Pending
- 2022-03-17 WO PCT/JP2022/012248 patent/WO2022202603A1/ja active Application Filing
- 2022-03-17 JP JP2022525275A patent/JPWO2022202603A1/ja active Pending
- 2022-03-17 US US18/283,231 patent/US20240173692A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07509173A (ja) * | 1992-06-19 | 1995-10-12 | セプラコア インコーポレーテッド | 表面処理および安定化した多孔質支持体,その製造法ならびに使用法 |
JP5420341B2 (ja) | 2009-08-04 | 2014-02-19 | 日機装株式会社 | 血球除去用吸着体及びその製造方法 |
JP2012224729A (ja) * | 2011-04-19 | 2012-11-15 | Asahi Kasei Medical Co Ltd | グラフト鎖を導入する方法、多孔質吸着膜、及びタンパク質の精製方法 |
JP2014207989A (ja) | 2013-03-29 | 2014-11-06 | 東レ株式会社 | タンパク質吸着材料およびその製造方法、血液浄化器 |
WO2016067967A1 (ja) | 2014-10-28 | 2016-05-06 | 東レ株式会社 | 多孔質繊維、吸着材料及び浄化カラム |
WO2016175306A1 (ja) * | 2015-04-30 | 2016-11-03 | 昭和電工株式会社 | タンパク質の精製方法 |
WO2017090658A1 (ja) * | 2015-11-24 | 2017-06-01 | Jsr株式会社 | 多孔質粒子の製造方法、多孔質粒子、担体、カラム、及び標的物質の分離方法 |
JP2019166520A (ja) * | 2018-03-23 | 2019-10-03 | 東レ株式会社 | バイオ医薬品精製システム |
WO2019225730A1 (ja) | 2018-05-24 | 2019-11-28 | 東レ株式会社 | 多孔質中空糸膜 |
JP2020006155A (ja) | 2018-07-02 | 2020-01-16 | 旭化成メディカル株式会社 | 血液処理用ビーズ |
Non-Patent Citations (1)
Title |
---|
KAZUHIRO ISHIKIRIYAMA ET AL., JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 171, 1995, pages 103 - 111 |
Also Published As
Publication number | Publication date |
---|---|
CN117177812A (zh) | 2023-12-05 |
US20240173692A1 (en) | 2024-05-30 |
JPWO2022202603A1 (ja) | 2022-09-29 |
EP4316646A1 (en) | 2024-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | Blood compatible aspects of DNA-modified polysulfone membrane—protein adsorption and platelet adhesion | |
JP5664732B2 (ja) | 分離膜及び分離膜モジュール | |
JP4699207B2 (ja) | 親水性微多孔膜 | |
JP6480447B2 (ja) | ヒストンを除去する吸着材及び生体由来液浄化デバイス | |
JP6036882B2 (ja) | 分離膜および分離膜モジュール並びに分離膜の製造方法および分離膜モジュールの製造方法 | |
JP5338431B2 (ja) | ポリスルホン系分離膜およびポリスルホン系分離膜モジュールの製造方法 | |
EP3766567A1 (en) | Porous hollow fiber membrane | |
KR102323265B1 (ko) | 다공질 섬유, 흡착 재료 및 정화 칼럼 | |
Lien et al. | A zwitterionic interpenetrating network for improving the blood compatibility of polypropylene membranes applied to leukodepletion | |
JP7013870B2 (ja) | 生体成分付着抑制材料 | |
JP2010104984A (ja) | ポリスルホン系中空糸膜モジュールおよび製造方法 | |
JP2010059395A (ja) | グラフト中空糸膜およびその製造方法 | |
JP6291970B2 (ja) | タンパク質吸着材料およびその製造方法、血液浄化器 | |
WO2022202603A1 (ja) | 多孔質吸着材料、およびそれを用いたバイオ医薬品精製用分離カラム、ならびに、バイオ医薬品の製造方法 | |
JP2022151744A (ja) | タンパク質吸着材料 | |
WO2023074562A1 (ja) | 中空糸膜、中空糸膜モジュール、およびベシクル含有溶液 | |
WO2021100804A1 (ja) | 多孔質分離膜 | |
JP6547518B2 (ja) | 中空糸膜モジュール及びその製造方法 | |
JPS61274707A (ja) | 微生物分離用再生セルロ−ス多孔膜 | |
JP2011183384A (ja) | 吸着材料および吸着材料の製造方法 | |
JPS63161972A (ja) | エイズウイルス分離濃縮用の再生セルロ−ス多孔膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2022525275 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22775391 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18283231 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022775391 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022775391 Country of ref document: EP Effective date: 20231026 |